Rhythm Management

Transforming lives with groundbreaking technologies that address irregular heart rhythms, heart failure and sudden cardiac arrest.
   
We are collaborating with healthcare professionals to help reduce costs, improve outcomes and enhance patients' lives with the most advanced and least invasive rhythm management technologies available.

Delivering Meaningful Innovation

Redefining Heart Care. We’re dedicated to helping patients live longer, healthier lives with the RHYTHMIA HDx™ Mapping System which provides physicians with the ability to diagnose arrhythmias with greater efficiency, delivers targeted therapy and confidently achieves procedural endpoints in complex substrates.

Improving Patient Management Through Personalized Care. Our MR-conditional Resonate™ family of implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) systems feature the HeartLogic™ Heart Failure Diagnostic to help physicians improve heart failure (HF) management. These devices also combine SmartCRT™ Technology and industry leading EnduraLife™ Battery Technology to improve patient management.

Pioneering Progressive ICD Therapy. The EMBLEM™ MRI S-ICD System is the first and only MR-conditional subcutaneous implantable defibrillator (S-ICD) that provides protection for patients at risk for sudden cardiac death while avoiding risks and complications associated with transvenous leads.

$1.95 Billion FY2018 Operational Sales

Conditions We Treat

  • Cardiac Arrhythmias
  • Heart Rhythm Disorders
  • Sudden Cardiac Arrest
  • Heart Failure
  

Solutions We Offer

  • Pacemakers
  • Implantable cardioverter defibrillators (ICDs)
  • Subcutaneous implantable defibrillator (S-ICD)
  • Cardiac resynchronization therapy defibrillators (CRT-Ds)
  • Remote monitoring systems
  • Pacing and ICD leads
  • Mapping and navigation system
  • Diagnostic and therapeutic catheters
  • Electrophysiology recording system
  • Intracardiac access sheaths
  • Pericardiocentesis kits

     
Activation Map
The RHYTHMIA HDxTM Mapping System provides unprecedented clarity to diagnose with greater efficiency, deliver targeted therapy and confidently achieve procedural endpoints in complex substrates.
Resonate X4
The ResonateTM family of implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) systems feature the HeartLogicTM Heart Failure Diagnostic. The Resonate devices, which are approved by the U.S. Food and Drug Administration for conditional use in a magnetic resonance imaging (MRI) environment, also combine the company's SmartCRTTM Technology with industry-leading EnduraLifeTM Battery Technology to improve patient management through personalized care.
Emblem MRI S-ICD System
The EMBLEMTM MRI S-ICD System is the first and only subcutaneous implantable defibrillator that provides protection for patients at risk for sudden cardiac death while avoiding risks and complications associated with transvenous leads.

Patient Impact

Emily's Story
Watch Emily's Story
  

Sources

* Ellis C, Markus T, Dickerman D, Orton J, Hassan S, Good E, Okabe T, Greenspon A. Ampere Hour as a Predictor of CRT ICD Pulse Generator Longevity: A Multi-Center Study. Presented at HFSA 2014. https://www.onlinejcf.com/article/S1071-9164(14)00337-6/fulltext. Ampere Hour (Ah) as a Predictor of CRT ICD Pulse Generator Battery Longevity Study. The five major institutions performing the study include, at Vanderbilt University, Eastside Cardiovascular Medicine, University of Michigan, Thomas Jefferson University, Robert Wood Johnson University Hospital, Cooper Health System and North Ohio Research. Boston Scientific = 266 patients, Medtronic = 542 patients, St. Jude Medical = 149 patients. Five-year survival rate calculated using device replacements for battery depletion as indicated by ERI.

** Modeling shows EnduraLife Technology saved the US healthcare system approximately $300 million in 2015. Avoided explants were modeled by comparing Boston Scientific's actual explant volumes in 2015 with those predicted by a model seeded with pre-EnduraLife longevities. Devices made by other manufacturers were not included in the model. Savings were quantified using an average reimbursement value for outpatient ICD replacement.

1. American Heart Association. Arrhythmia. https://www.heart.org/Arrhythmia. Accessed June 22, 2014.

2. American Heart Association. Heart Disease and Stroke Statistics – 2014 Update. Circulation. 2014;129:e28-e292.

3. American Heart Association. Heart Disease and Stroke Statistics – 2014 Update. Circulation. 2014;129:e28-e292.

Top